Цисплатин is a platinum-based chemotherapy drug that plays a role in managing several forms of cancer. The main therapeutic domains are related to cancer management and may assist with maintaining functional stability for patients.

Key Therapeutic Applications and Benefits

Цисплатин is commonly used for the treatment of bladder, ovarian, and testicular cancers, alone or in combination with other agents. It is generally used across conditions presenting with advanced or metastatic episodes. Applied in clinical settings that involve acute or unstable symptom patterns, this use may help ease the overall symptom burden and assists with maintaining functional stability associated with the condition.

Beyond its primary applications, Cisplatin is also used in areas where short-term symptom management is appropriate for other condition categories. It is relevant in clinical settings marked by heightened systemic burden.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns where supportive symptom management is appropriate.”

Quick Fact: Supports functional stability during episodes.

Regulatory References

1. National Cancer Institute (NCI) Drug Information

Eligibility Map: Who can and cannot use Cisplatin — Official Regulatory Information

Cisplatin is contraindicated and must not be used in patients with the following conditions, as stated in authoritative government regulatory documents:

• A history of hypersensitivity or severe allergic reactions to Cisplatin itself or any other platinum-containing compounds.
• Pre-existing Renal Impairment (kidney dysfunction). Repeat courses are restricted until serum creatinine and blood urea nitrogen (BUN) levels meet specific recovery thresholds.
• Myelosuppression (severe depression of bone marrow function, resulting in low blood cell counts).
• Hearing Impairment or other hearing disorders, due to the drug's cumulative ototoxicity.

---

Population-Specific Limitations

Population Group	Eligibility Status & Restriction (Official Labeling)
Pregnancy	Contraindicated (Can cause fetal harm). Females of reproductive potential must use effective contraception during and for a specified time after therapy.
Lactation	Contraindicated; breastfeeding is not recommended.
Pediatric Patients	Safety and effectiveness are often not established. Pediatric patients may be at greater risk for severe ototoxicity.
Older Adults	Use requires caution. Elderly patients may be more susceptible to toxicities like nephrotoxicity and peripheral neuropathy.
Repeat Courses	Restricted. Subsequent doses are not given until hematologic parameters (WBC and platelets) and renal function have recovered to acceptable levels.

Interactions with other medicines and products

The interaction profile of Cisplatin is defined by regulatory documents based on additive toxicity risks and chemical incompatibility, rather than metabolic enzyme effects.

Official Interaction Restrictions

Classification	Interacting Agents/Products	Nature of Interaction/Restriction
Contraindicated	Live Vaccines (e.g., yellow fever)	Increased risk of serious or fatal infection due to Cisplatin's immunosuppressive effects.
	Aluminum-containing materials	Chemical reaction forming an inactive precipitate; must be strictly avoided during preparation and administration.
Caution/Avoidance	Ototoxic agents (e.g., Aminoglycosides, Loop Diuretics)	Additive risk of cumulative damage to the inner ear (ototoxicity).
	Nephrotoxic agents (e.g., Amphotericin B, Contrast Media)	Additive risk of damage to the kidneys (nephrotoxicity).

Timing and Population Notes

The co-administration of Palifermin has a mandated 24-hour separation rule relative to Cisplatin infusion. Some anti-seizure medications, such as phenytoin, may experience reduced plasma levels when co-administered. Regulatory cautions note that the risks of interaction-related toxicities (nephrotoxicity and ototoxicity) are officially documented to be more clinically significant in elderly patients and children when combined with other toxic agents.

The action of Цисплатин operates through genotoxic cytotoxicity, involving the targeting of genetic material in proliferating cells. Its mechanism unfolds across three core mechanistic domains, resulting in the physiological outcome of cellular destruction.

DNA Cross-Linking and Damage

The mechanism begins with Цисплатин directly binding to the N7 position of guanine bases on the cell's DNA, acting as a platinum-based cross-linker. This action creates bulky DNA adducts that severely distort the double helix structure.

Inhibition of Cell Replication and Transcription

The physical damage to the DNA helix prevents the necessary unwinding and separation required for DNA replication and RNA transcription. This structural blockade stalls the cell's machinery, triggering the DNA Damage Response (DDR) system and forcing the cell into G2/M phase arrest. This blockade affects cellular processes, leading to the inhibition of proliferation.

Inducing Programmed Cell Death (Apoptosis)

When the DNA damage is deemed irreparable by the cell's surveillance system (DDR), the damage signal activates the Intrinsic Apoptosis Pathway. This cascade leads to the activation of caspases and the systematic self-dismantling of the cell. This process results in apoptosis—the organized programmed death of susceptible cells.

How to Use Cisplatin: Official Administration Guidelines

Cisplatin is administered strictly according to established protocols. The usage focuses on precise dosing, mandatory hydration, and specific procedural controls.

---

Administration Scope

Feature	Official Requirement
Route	Primarily Intravenous (IV) Infusion. Intraperitoneal instillation is used in specific settings.
Dosing	Calculated based on Body Surface Area (BSA) (e.g., 50-120 mg/m^2) for single-agent therapy or reduced doses for combination therapy.
Frequency	Intermittent dosing, typically once every 3 to 4 weeks, provided specific pre-treatment laboratory criteria are met.

---

Procedural and Handling Requirements

Administration involves essential preparatory steps and conditions. Cisplatin concentrate must be diluted in a compatible solution, most often 0.9% Sodium Chloride injection, prior to infusion.

Condition	Requirement
Hydration	Mandatory aggressive intravenous hydration both before and after administration (e.g., 1-2 liters pre-treatment) to support kidney function and urinary output.
Infusion Rate	Administered by slow IV infusion, generally over a period of 6 to 8 hours.
Equipment	Strictly prohibited from contact with aluminum to prevent a chemical reaction that can cause precipitation and product degradation.
Lab Criteria	Subsequent doses are contingent upon meeting specific laboratory values (e.g., adequate serum creatinine, platelet, and white blood cell counts).
Pediatric Use	Requires close monitoring of hearing (audiometry) due to heightened risk in younger patients.

Research Evidence / Overview of Studies for Цисплатин

Evidence for Use in Bladder Cancer

Research has examined Цисплатин in various settings for bladder cancer, focusing on outcomes related to systemic or functional imbalance. Many studies were evaluated in populations where the cancer had advanced or had recurred, or as part of a study regimen before or after surgery. Findings describe patterns observed in the studies where patients were evaluated in Цисплатин-containing regimens. Research so far indicates that this approach was studied for its role in patient-reported outcomes describing perceived discomfort. Evidence quality varies across studies, and some long-term comparisons are still emerging.

Evidence for Use in Ovarian Cancer

For ovarian cancer, which is a condition involving periods of heightened symptoms, Цисплатин was evaluated in studies focused on initial therapy. Research highlights changes measured during the study period concerning outcomes reflecting daily functioning or activity level. The research data show patterns related to how the condition evolved in the observed populations. Certain studies suggest that this type of chemotherapy was observed in some studies to be a widely evaluated in the research. Findings were mixed regarding certain long-term metrics, and data are still emerging from trials that compare different schedules or drug combinations.

Evidence for Use in Testicular Cancer

This heading will present a summary of the clinical evidence regarding research involving Цисплатин-based regimens for patients diagnosed with testicular cancer. Historically, key clinical trials research examined its role in regimens that have been widely evaluated in clinical research. The evidence contributes to the broader evidence landscape by providing detailed records of the outcomes describing episodic or acute changes across various stages of the condition. While the role of Цисплатин is well-established in this area of research, follow-up durations were limited in some initial trials.

Long-term Studies and Follow-up

Studies used in research exploring how symptoms change over time often include planned follow-up periods to understand outcomes that appear later. The evidence highlights what is known — and what is still uncertain about outcomes over time. Long-term effects are not fully established regarding certain effects that may only appear or become noticeable years after the study period concluded. Results apply only to the populations studied, and research does not determine whether an individual will respond similarly.

What is Still Uncertain About Цисплатин

Despite decades of research, key areas of uncertainty remain in the findings. Research is ongoing to clarify the optimal timing and dosing schedules, especially when Цисплатин is used alongside newer targeted therapies. Evidence quality varies across studies, and for many specific combinations or rare cancer subtypes, comparative evidence is lacking.

Key Studies & References

1. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)
2. Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives

Common questions about Цисплатин (FAQ)

---

Q: What is Цисплатин (Cisplatin) used to treat?

According to the official product information, Cisplatin is a chemotherapy medication used to treat several types of cancer. These typically include advanced testicular cancer, advanced ovarian cancer, and advanced bladder cancer. It is also used in combination with other therapeutic agents for certain head and neck cancers, cervical cancer, and non-small cell lung cancer.

---

Q: How is Цисплатин given to the patient?

Cisplatin is administered to the patient through an intravenous (IV) infusion, meaning the medication is given directly into a vein. Regulatory documents state that this procedure must be conducted by trained medical professionals in a monitored clinic or hospital setting. The medication is usually diluted in a solution before the infusion process begins.

---

Q: Does Цисплатин need to be given with other medications?

Studies and official information indicate that Cisplatin is often used as part of a combination chemotherapy regimen, meaning it is administered alongside other cancer drugs. In some cases, supportive medications are administered alongside Cisplatin. This may include treatments designed to help manage potential side effects related to the therapy.

---

Q: What happens if I miss a scheduled dose of Цисплатин?

Cisplatin is given on a specific schedule determined by a medical team. Regulatory documents indicate that if a scheduled treatment is missed, the patient should inform the treating physician as soon as possible. The physician will then determine the appropriate next steps for adjusting the treatment schedule based on the individual's condition and treatment plan.

---

Q: Can I receive Цисплатин if I have kidney problems?

According to the official product information, Cisplatin is generally contraindicated (should not be used) in patients who have pre-existing severe kidney impairment. Because Cisplatin carries a risk of nephrotoxicity (kidney damage), blood tests are typically performed before and during treatment to monitor kidney function. Treatment suitability is assessed by the physician based on these test results and regulatory guidance.

---

Q: Can I receive Цисплатин if I have hearing problems or Tinnitus?

Cisplatin has the potential to cause ototoxicity, which is damage to the inner ear that can lead to hearing loss and Tinnitus (ringing in the ears). Official sources state that it is generally contraindicated in patients with pre-existing severe hearing impairment. Official guidance often recommends audiological tests (hearing tests) be performed before and during therapy to monitor for potential hearing changes.

---

Q: Is it safe to get a vaccine while I am on Цисплатин?

Chemotherapy treatments can affect the immune system. Regulatory documents indicate that the use of live vaccines is generally contraindicated during Cisplatin treatment. Any decisions regarding vaccination during or shortly after Cisplatin therapy should be made in consultation with the treating physician to ensure patient safety.

---

Q: What tests are done before and during Цисплатин treatment?

Before starting and throughout treatment, doctors must monitor several aspects of the patient’s health due to the known risks of Cisplatin. Official product information requires frequent checks of blood counts, kidney function markers (like creatinine clearance), liver function, and hearing ability (audiometry). These regular tests help the medical team ensure the treatment remains safe to continue.

---

Q: Should I drink more water while being treated with Цисплатин?

Hydration protocols are a crucial component of Cisplatin treatment. Your medical team will typically administer a large volume of fluids (hydration) intravenously around the time of the infusion. Maintaining adequate fluid intake is noted in regulatory information as a critical safety measure intended to help protect the patient's kidneys from damage.

Official Storage and Disposal Requirements

Labeled Storage Temperature Requirements	20 C to 25 C (Controlled Room Temperature).
Light Protection and Prohibited Environments	Protect from light and do not refrigerate or freeze to prevent precipitation.
Stability After Opening	The solution in the punctured vial is stable for 28 days when continuously protected from light or 7 days under normal room light, stored at 15 C to 25 C.
Handling and Safety	Keep the product out of the sight and reach of children. Must be handled according to special procedures for cytotoxic drugs.
Disposal Requirements	As a cytotoxic drug, disposal of unused product and contaminated waste must follow specialized handling and disposal procedures as per local regulations. Items used for preparation must be discarded via designated hazardous waste protocols, often including high-temperature incineration.